Team Project

Biomarkers for early detection of pancreatic cancer

Biomarkers for early detection of pancreatic cancer
ALCAM, AFP, CA 19-9, CA 72-4, CA125, CEA, CEACAM-1, CEACAM-6, CYFRA 21-1, HE4, Apo CIII, E, Complement C4, CRP, transthyretin (TTR), FSH, GH, bHCG, prolactin (PRL), EGFR, ErbB2, FGF2, HGF, IGFBP-3, VEGFR1, 2, 3, TGFα, Fas, FasL, clusterin, IL-8, MIF, MPO, IL-1R1, IL-4R, IL-6R, TNFRI, TNFRII, YKL40, MIC-1, MIP-4, HIF-1α, MMP-3, 9, TIMP-1-4, tPAI1, NGAL, ICAM-1, VCAM-1, NCAM, Periostin, Cathepsin D, Insulin, PTH, AGRP, BDNF, CNTF, NSE, Osteocalcin (OC), osteoprotegerin (OPG), osteonectin (OSN), osteopontin (OPN), TRAP5, Galectin-3, FAPalpha, MIA, SHBG, Ferritin
No design specified.
G.I. and Other Associated Cancers Research Group

To identify biomarkers of preclinical pancreatic cancer

1. Validate biomarkers identified in case/control set in preclinical proximal PLCO samples 2. Optimize biomarkers for maximal classification of preclinical disease

There are currently no biomarkers annotated for this protocol.

Version 5.1.0